Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Combined Treatments for Somatosensory Tinnitus

12. november 2026 oppdatert av: Andriele dos Santos Cavalheiro, Universidade Federal de Santa Maria

Placebo-controlled Clinical Trial: an Analysis of Combined Treatments for Somatosensory Tinnitus

The purpose of this clinical trial is to evaluate whether a combination of manual therapies, therapeutic exercises, and integrative and complementary practices reduces the loudness, discomfort, and impact of somatosensory tinnitus. This type of tinnitus is associated with changes in the neck and/or jaw joint.

The main questions this study aims to answer are:

Does the combined treatment reduce tinnitus loudness, discomfort, and impact more than placebo?

Are the benefits maintained three months after treatment ends?

Researchers will compare two groups: one will receive the combined treatment targeting the neck and jaw regions, and the other will receive simulated procedures (placebo) that resemble the treatment procedures.

Participants will:

Attend one session per week for 12 weeks (three months), receiving either the combined treatment or placebo, depending on the group to which they are randomly assigned.

Complete questionnaires before and at the end of the 12 weeks.

Return for a follow-up assessment three months after the sessions end to determine whether the effects have been maintained.

Studieoversikt

Detaljert beskrivelse

Somatosensory tinnitus is a form of tinnitus in which sensory input from the neck or jaw can influence the perceived sound. In some individuals, tinnitus changes during neck or jaw movements or in response to pressure on specific muscles. The clinical rationale for this trial is to address these musculoskeletal factors alongside the burden of tinnitus in daily life.

The treatment program combines manual therapies, therapeutic exercise, and integrative and complementary practices. These approaches were selected to address different aspects of the condition within the same program, including muscle tension, movement and function of the neck and jaw, and how participants respond to tinnitus. The study hypothesis is that these complementary approaches may provide greater benefit when delivered as a combined program than the simulated procedures used as the placebo control.

This placebo-controlled clinical trial will compare the effects of the combined program and the simulated procedures in adults with somatosensory tinnitus. The study will evaluate changes in perceived tinnitus loudness, tinnitus-related bothersomeness, and the impact of tinnitus on daily life. Follow-up will assess whether any improvements observed at the end of treatment are maintained.

Studietype

Intervensjonell

Registrering (Antatt)

52

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Rio Grande do Sul
      • Santa Maria, Rio Grande do Sul, Brasil, 97105-900
        • Rekruttering
        • Federal University of Santa Maria - Speech-Language Pathology and Audiology Service
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Participants of either sex;
  • Aged 18 years or older;
  • Normal hearing thresholds or sensorineural hearing loss up to severe degree, provided that participants can understand verbal instructions and mindfulness recordings;
  • Positive screening for somatosensory tinnitus;
  • Presence of one or more active or latent myofascial trigger points in the head, neck, and/or shoulder girdle;
  • A Visual Analog Scale (VAS) score greater than 5 for tinnitus-related discomfort or perceived tinnitus loudness.

Exclusion Criteria:

  • Physical therapy for tinnitus, temporomandibular disorders, or neck pain within the 30 days preceding the assessment;
  • Ongoing treatment using any of the techniques proposed in the study;
  • Positive screening for vascular tinnitus;
  • A diagnosed ear, nose, or throat condition underlying the tinnitus;
  • Neurological conditions potentially causing tinnitus;
  • Inability to read, understand, and complete the questionnaires or to understand and follow instructions, for example, due to illiteracy, dementia, or blindness;

Fibromyalgia;

Previous negative experiences with needles used for therapeutic purposes;

A formal contraindication to dry needling, such as chronic anticoagulant use or hematological disorders;

Altered sensation.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Enkelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: G1-Combined Treatment

Participants will receive 12 weekly sessions over three months. During the first month, treatment will combine mindfulness and myofascial release. During the second month, treatment will combine mindfulness and Pilates exercises. During the third month, treatment will combine auriculotherapy and dry needling. The physical interventions will target the cervical and temporomandibular regions.

This intervention is part of the G1 intervention group and consists of seven sessions using guided mindfulness recordings. Participants will be instructed to practice once daily. The recordings will be replaced weekly and sent via WhatsApp. Each recording lasts between 3 and 15 minutes.

Counseling is part of the G1 intervention and will be delivered individually during the first session, lasting 15 minutes. Guidance will be tailored to each participant's needs to encourage adherence to the proposed practices and changes in behaviors and lifestyle habits that may contribute to worsening tinnitus.

Myofascial release is part of the G1 intervention and will be delivered in four sessions. Myofascial trigger points will be treated using gradually increasing, sustained digital pressure until the participant reports no tenderness at the site, followed by manual techniques along the taut muscle band. Target muscles will include the infraspinatus, levator scapulae, upper trapezius, splenius capitis, splenius cervicis, sternal head of the sternocleidomastoid, superficial masseter, anterior temporalis, and lateral and medial pterygoids. Myofascial release will last 30 minutes during the first session, which will also include counseling and an introduction to mindfulness. Each of the remaining three sessions will include 40 minutes of myofascial release.

Pilates is part of the G1 intervention and will be delivered during the second month of treatment, comprising four weekly 40 minutes sessions at the tinnitus outpatient clinic. Mat-based exercises will use a mat, a small exercise ball, and 1-kg dumbbells, with adaptations for individuals with tinnitus, neck pain, and muscle tension. Each exercise will be performed in one set of 10, 15, or 20 repetitions, adjusted to the participant's fitness level and reported pain and fatigue. Sessions will include preparatory pre-Pilates and breathing exercises, basic exercises incorporating Pilates principles, and final stretching. Participants with temporomandibular disorders will also receive specific temporomandibular joint exercises and instructions to perform them at home once daily until the end of treatment.

Auriculotherapy is part of the G1 intervention and will be delivered during the third month of treatment in four weekly 10-minute sessions. Auricular points will be selected based on Traditional Chinese Medicine and previous studies addressing tinnitus and muscle tension in the cervical, thoracic, and temporomandibular regions. Mustard seeds will be secured to the ear with microporous adhesive tape, alternating between the right and left ears each week. Participants will be instructed to keep the seeds in place for up to three days and press each auricular point 15 times, at least three times daily.

Dry needling is part of the G1 intervention and will be delivered during the third month of treatment in four weekly sessions alongside auriculotherapy. Sterile, single-use, disposable acupuncture needles measuring 0.20 × 30 mm (DUX) will be used. The therapist will wear gloves, and the skin will be disinfected with 70% w/w alcohol. Participants will be positioned supine for needling of the upper trapezius, sternocleidomastoid, masseter, and lateral pterygoid; prone for the upper trapezius and infraspinatus; and side-lying for the splenius capitis, splenius cervicis, and levator scapulae.

Placebo komparator: G2- Sham Treatment

Participants will receive 12 weekly sessions over three months. During the first month, they will listen to relaxation recordings matched in duration to the mindfulness practices in the intervention group and receive manual manipulation without trigger point deactivation techniques. During the second month, they will listen to the same types of recordings and perform gentle, unloaded movements, including upper limb, lower limb, and spinal stretching. During the third month, they will receive microporous adhesive tape applied to the ear without stimulation of auricular points and superficial skin needling in the abdominal, quadriceps, and gastrocnemius regions.

This intervention is part of the G2 control group and consists of listening to relaxation recordings selected from YouTube during the first and second months of treatment. The recordings will be matched in duration to the mindfulness practices used in the G1 intervention group. Participants will be instructed to listen once daily. The recordings will be replaced weekly and sent via WhatsApp.

This intervention is part of the G2 control group and will be delivered during the first month of treatment in four weekly sessions. Participants will receive manual manipulation without myofascial trigger point deactivation techniques. Session duration will match that of myofascial release in G1: 30 minutes in the first session and 40 minutes in each of the remaining three sessions.

This intervention is part of the G2 control group and will be delivered during the second month of treatment in four weekly 40 minutes sessions. Participants will perform gentle, unloaded movements, including upper limb, lower limb, and spinal stretching, as a comparison intervention to the Pilates exercises performed by the G1 group.

This intervention is part of the G2 control group and will be delivered during the third month of treatment in four weekly sessions. Microporous adhesive tape will be applied to the ear without seeds or stimulation of auricular points, as a sham comparison to auriculotherapy in the G1 group.

This intervention is part of the G2 control group and will be delivered during the third month of treatment in four weekly sessions, alongside auricular tape application without stimulation. Participants will receive superficial skin needling in the abdominal, quadriceps, and gastrocnemius regions as a comparison procedure to dry needling in the G1 group.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change in Tinnitus Discomfort Visual Analog Scale Score
Tidsramme: Baseline, immediately after completion of the 12-week treatment, and three months after treatment completion.

Tinnitus-related discomfort will be assessed using a visual analog scale (VAS) ranging from 0 to 10. Higher scores indicate greater discomfort. A decrease in score from baseline indicates improvement.

Baseline, immediately after completion of the 12-week treatment, and three months after treatment completion.
Change in Tinnitus Loudness Visual Analog Scale Score
Tidsramme: Baseline, immediately after completion of the 12-week treatment, and three months after treatment completion.

Perceived tinnitus loudness will be rated on a visual analog scale ranging from 0 to 10. Higher scores indicate greater perceived loudness. A reduction from baseline indicates improvement.

Baseline, immediately after completion of the 12-week treatment, and three months after treatment completion.
Change in Tinnitus Handicap Inventory Total Score
Tidsramme: Baseline, immediately after completion of the 12-week treatment, and three months after treatment completion.

Handicap Inventory Total Score The 25-item Tinnitus Handicap Inventory will assess tinnitus-related handicap. Total scores range from 0 to 100, with higher scores indicating greater handicap. A reduction from baseline indicates improvement.

Baseline, immediately after completion of the 12-week treatment, and three months after treatment completion.
Change in Tinnitus Functional Index Total Score
Tidsramme: Baseline, immediately after completion of the 12-week treatment, and three months after treatment completion.

The 25-item Tinnitus Functional Index will assess tinnitus severity and functional impact. Total scores range from 0 to 100, with higher scores indicating greater impact. A reduction from baseline indicates improvement.

Baseline, immediately after completion of the 12-week treatment, and three months after treatment completion.
Change in Hospital Anxiety and Depression Scale Anxiety and Depression Subscale Scores
Tidsramme: Baseline, immediately after completion of the 12-week treatment, and three months after treatment completion.

Anxiety and depressive symptoms will be assessed using the Hospital Anxiety and Depression Scale (HADS), a 14-item questionnaire comprising two seven-item subscales. Each subscale ranges from 0 to 21, with higher scores indicating more severe symptoms. Changes from baseline will be assessed separately for anxiety and depression.

Baseline, immediately after completion of the 12-week treatment, and three months after treatment completion.

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change in Neck Disability Index Total Score
Tidsramme: Baseline, immediately after completion of the 12-week treatment, and three months after treatment completion.

Neck-related disability will be assessed using the 10-item Neck Disability Index. Raw total scores range from 0 to 50, with higher scores indicating greater disability. A reduction from baseline indicates improvement.

Baseline, immediately after completion of the 12-week treatment, and three months after treatment completion.
Change in Maximum Skin Temperature Assessed by Infrared Thermography
Tidsramme: Baseline, immediately after completion of the 12-week treatment, and three months after treatment completion.

Maximum skin temperature, in degrees Celsius (°C), will be assessed using infrared thermography over the surface regions corresponding to the infraspinatus, levator scapulae, upper trapezius, splenius capitis, splenius cervicis, sternal head of the sternocleidomastoid, superficial masseter, and anterior temporalis. Images will be acquired with participants standing, using anterior, posterior, and lateral views to evaluate temperature changes following treatment.

Baseline, immediately after completion of the 12-week treatment, and three months after treatment completion.

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Generelle publikasjoner

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

10. januar 2025

Primær fullføring (Antatt)

1. juni 2027

Studiet fullført (Antatt)

1. desember 2027

Datoer for studieregistrering

Først innsendt

7. november 2026

Først innsendt som oppfylte QC-kriteriene

12. november 2026

Først lagt ut (Faktiske)

17. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

17. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

12. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

UBESLUTTE

IPD-planbeskrivelse

A decision regarding the sharing of individual participant data has not yet been made. The research team will evaluate the feasibility and conditions for data sharing.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere